Author: BusinessWire

Preliminary Data from Single-Ascending Dose Cohorts Expected Later this Year
CAMBRIDGE, Mass. & LAUSANNE, Switzerland–(BUSINESS WIRE)–Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune toleran…

Preliminary Data from Single-Ascending Dose Cohorts Expected Later this Year
CAMBRIDGE, Mass. & LAUSANNE, Switzerland–(BUSINESS WIRE)–Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune toleran…

Preliminary Data from Single-Ascending Dose Cohorts Expected Later this Year
CAMBRIDGE, Mass. & LAUSANNE, Switzerland–(BUSINESS WIRE)–Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune toleran…

MENLO PARK, Calif.–(BUSINESS WIRE)–GRAIL, Inc., a healthcare company whose mission is to detect cancer early, announced today it is joining forces with AccessHope™ to offer a world-class service experience to people who use Galleri™, GRAIL’s first-of…

RENAsym SAB to Provide Insights and Guidance for Development of Kidney Injury Software
LANCASTER, Calif.–(BUSINESS WIRE)–Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical saf…

First-in-human Trial with Novel Glaucoma Treatment Confirmed Favorable Safety Profile and Signaled Efficacy
SAN DIEGO–(BUSINESS WIRE)–Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused o…

First-in-human Trial with Novel Glaucoma Treatment Confirmed Favorable Safety Profile and Signaled Efficacy
SAN DIEGO–(BUSINESS WIRE)–Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused o…

— Commercial formulary coverage effective May 15, 2021 —
WATERTOWN, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for…

Acceptance Clears Path for Initiation of Phase 2 Clinical Trial for BRIMOCHOL
SEATTLE–(BUSINESS WIRE)–Visus Therapeutics Inc. (the “Company”), a clinical-stage pharmaceutical company in pursuit of developing the world’s first presbyopia-correcting e…

Acceptance Clears Path for Initiation of Phase 2 Clinical Trial for BRIMOCHOL
SEATTLE–(BUSINESS WIRE)–Visus Therapeutics Inc. (the “Company”), a clinical-stage pharmaceutical company in pursuit of developing the world’s first presbyopia-correcting e…